In addition, the major new finding of this study is that in parallel with disease progression in patients with MS, the level of inflammatory markers as well as adipocytokines including resistin and leptin decreased and the expression of FoxP3 and circulating level of visfatin increased. This evidence concerns the gene LEP and myeloid sarcoma.